Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-25

Study Completion Date

2025-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a monocenter, randomized, controlled, parallel-group, double-masked clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation at baseline compared to a single vision spectacle lens (control). A total of 80 children will be recruited where 40 subjects will be allocated either to wear test lenses (group 1) or control lenses (group 2) for 1 year through randomization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.

NCT05534022

Myopia

ACTIVE_NOT_RECRUITING NA

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (CSL)

NCT05724186

Myopia

COMPLETED NA

Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression (DAL)

NCT05840185

Myopia

ACTIVE_NOT_RECRUITING NA

Exploratory Study on the Effectiveness of Myopia Control Lenses in Slowing Myopia Progression in Young Children

NCT06857864

Myopia

ACTIVE_NOT_RECRUITING NA

Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression

NCT06850168

Myopia

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As myopia is a growing worldwide problem, it is important to better understand the range of possible treatments to slow the progression of myopia. Spectacle lenses with aspherical lenslets were shown to be effective in reducing myopia progression and axial length elongation in children in the previous clinical trial. A dose-dependent effect was demonstrated, with higher lenslet asphericity having greater myopia control efficacy.

This double masked parallel group study will test the safety and effectiveness of a test lens designed to modify the area and amount of myopic defocus on the retina without compromising vision. The study population includes children in Singapore aged 8 to 13 years (80 subjects) at the time of commencing treatment. As age of myopia onset is known to be an important factor in rate of myopia progression, subject age at the time of enrollment will be used to balance randomization. Axial length and spherical equivalent refraction will be the primary measure for myopia progression. Visual acuity will also be compared between test lenses and control lenses to determine the quality of vision using test lenses.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia, Progressive Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a randomized, controlled, 2-armed, double-masked, monocenter, clinical trial, which consists of 6 visits across 1 year. The test myopia control lens will be compared with a single vision control lens in evaluating study objectives. After obtaining informed consent and assent, a comprehensive eye examination for screening will be done among approximately 80 myopic children between the age of 8-13 years old for eligibility. After randomization, the subjects will be back for dispensing of study spectacles and for baseline visit, where assessment of study spectacles, biometry, and instructions to use study spectacles were done. A follow up visit will be conducted in 3, 6 and 12 months time, in which the latter visit will also be the end of visit. All of which are non-contact and non-invasive to the eyes.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Subjects (and their parents/guardians) will be masked to the lens assignment. Sibling of subjects must be excluded due to the noticeable differences between the test and control spectacle lenses Only the statistician will be unmasked when comparing the two lenses. The investigator who is responsible for randomization and allocation will also be unmasked. However, the primary outcome variables (spherical equivalent refraction \& axial length) will be taken by masked investigators. To facilitate this, the subject will be led into the room(s) containing a biometer without their study spectacles by the unmasked investigator.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test myopia control lenses

A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.

Group Type EXPERIMENTAL

Test myopia control lenses

Intervention Type DEVICE

A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.

Single vision lenses

A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.

Group Type OTHER

Single vision lenses

Intervention Type DEVICE

A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Test myopia control lenses

A myopia control spectacle lenses (test lenses) will be given to 1 arm to wear for 12 months.

Intervention Type DEVICE

Single vision lenses

A single vision spectacle lenses (control lenses) will be given to 1 arm to wear for 12 months.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteer subject and guardian, fluent English spoken, willing to follow protocol and able to read, comprehend and sign the informed consent \& assent form.
* Equal to or greater than 8 years and not older than 13 years at time of informed consent and assent.
* Spherical equivalent refractive error (SER) by manifest refraction between -0.75 and -4.75 D in each eye.
* Astigmatism, if present, of not more than 1.50 D.
* Difference in SER between the two eyes (Anisometropia) by manifest refraction not more than 1.00 D.
* Best corrected visual acuity in each eye equal to or better than +0.10 logMAR (≥ 20/25 as Snellen)
* Be in good general health based on his/her and parent's/guardian's knowledge. Absence of ocular disease with full ophthalmic examination. Without any ocular or systemic condition known to affect refractive status.
* History of myopia control intervention
* Absence of strabismus by cover test at near or distance wearing correction.
* Absence of amblyopia
* Without ocular or systemic medications which, in the investigator's opinion, may significantly affect pupil size, accommodation or refractive state.

Exclusion Criteria

* Vulnerability of subject
* Participation in any clinical study within 30 days of the Baseline visit.
* Sibling of existing participant of this study

Minimum Eligible Age

8 Years

Maximum Eligible Age

13 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes